Emmes partners with ILiAD Biotechnologies for global Phase III trials of next-gen pertussis vaccine BPZE1

New Delhi: ILiAD Biotechnologies, LLC has announced a collaboration with Emmes Group to conduct Phase III clinical trials of its promising pertussis vaccine candidate, BPZE1. These trials will take place across multiple regions, including North America, Central and South America, the UK, and other global sites.

Dr. Keith Rubin, CEO of ILiAD Biotechnologies, stated, “Selecting Emmes Group for our Phase III BPZE1 trials has been a carefully considered strategic decision to ensure the highest standards of clinical research. VaxTrials’ specialization in vaccines and Veridix AI’s advanced technological capabilities will be instrumental in executing our BPZE1 vaccine clinical development plan.”

Sastry Chilukuri, CEO of Emmes Group, expressed, “We are honored and pleased that ILiAD has selected Emmes Group as its partner to continue the clinical development of BPZE1. We look forward to working closely with ILiAD’s clinical development team on this promising new vaccine, which could significantly reduce the transmissibility and incidence of B. pertussis, particularly in vulnerable populations.”

ILiAD’s choice of Emmes follows the successful support provided by VaxTrials during the Phase II IB-201P BPZE1 study, showcasing the unit’s proficiency and excellence in clinical trials. The upcoming Phase III studies aim to further validate BPZE1’s effectiveness in preventing pertussis, with hopes of significantly impacting public health by reducing the spread and incidence of this highly contagious respiratory disease.

Emmes Group was chosen for its extensive expertise in vaccine development, adept management of complex clinical trials, and robust presence in local markets. The collaboration will leverage the capabilities of Emmes’ VaxTrials unit and Veridix AI, both integral parts of the Emmes Group, to provide comprehensive clinical research services and advanced eClinical platform capabilities, respectively.